Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

Peter Valent, Attilio Orazi, David P. Steensma, Benjamin L. Ebert, Detlef Haase, Luca Malcovati, Arjan A. van de Loosdrecht, Torsten Haferlach, Theresia M. Westers, Denise A. Wells, Aristoteles Giagounidis, Michael Loken, Alberto Orfao, Michael Lübbert, Arnold Ganser, Wolf Karsten Hofmann, Kiyoyuki Ogata, Julie Schanz, Marie C. Béné, Gregor Hoermann & 9 others Wolfgang R. Sperr, Karl Sotlar, Peter Bettelheim, Reinhard Stauder, Michael Pfeilstöcker, Hans Peter Horny, Ulrich Germing, Peter Greenberg, John M. Bennett

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid neoplasms characterized by peripheral cytopenia, dysplasia, and a variable clinical course with about 30% risk to transform to secondary acute myeloid leukemia (AML). In the past 15 years, diagnostic evaluations, prognostication, and treatment of MDS have improved substantially. However, with the discovery of molecular markers and advent of novel targeted therapies, new challenges have emerged in the complex field of MDS. For example, MDS-related molecular lesions may be detectable in healthy individuals and increase in prevalence with age. Other patients exhibit persistent cytopenia of unknown etiology without dysplasia. Although these conditions are potential pre-phases of MDS they may also transform into other bone marrow neoplasms. Recently identified molecular, cytogenetic, and flow-based parameters may add in the delineation and prognostication of these conditions. However, no generally accepted integrated classification and no related criteria are as yet available. In an attempt to address this challenge, an international consensus group discussed these issues in a working conference in July 2016. The outcomes of this conference are summarized in the present article which includes criteria and a proposal for the classification of pre-MDS conditions as well as updated minimal diagnostic criteria of MDS. Moreover, we propose diagnostic standards to delineate between 'normal', pre-MDS, and MDS. These standards and criteria should facilitate diagnostic and prognostic evaluations in clinical studies as well as in clinical practice.

Original languageEnglish
Pages (from-to)73483-73500
Number of pages18
JournalOncotarget
Volume8
Issue number43
DOIs
Publication statusPublished - 2017

Cite this

Valent, P., Orazi, A., Steensma, D. P., Ebert, B. L., Haase, D., Malcovati, L., ... Bennett, J. M. (2017). Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget, 8(43), 73483-73500. https://doi.org/10.18632/oncotarget.19008
Valent, Peter ; Orazi, Attilio ; Steensma, David P. ; Ebert, Benjamin L. ; Haase, Detlef ; Malcovati, Luca ; van de Loosdrecht, Arjan A. ; Haferlach, Torsten ; Westers, Theresia M. ; Wells, Denise A. ; Giagounidis, Aristoteles ; Loken, Michael ; Orfao, Alberto ; Lübbert, Michael ; Ganser, Arnold ; Hofmann, Wolf Karsten ; Ogata, Kiyoyuki ; Schanz, Julie ; Béné, Marie C. ; Hoermann, Gregor ; Sperr, Wolfgang R. ; Sotlar, Karl ; Bettelheim, Peter ; Stauder, Reinhard ; Pfeilstöcker, Michael ; Horny, Hans Peter ; Germing, Ulrich ; Greenberg, Peter ; Bennett, John M. / Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. In: Oncotarget. 2017 ; Vol. 8, No. 43. pp. 73483-73500.
@article{5db67f6c92db45568884cf6a7bfdad6e,
title = "Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions",
abstract = "Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid neoplasms characterized by peripheral cytopenia, dysplasia, and a variable clinical course with about 30{\%} risk to transform to secondary acute myeloid leukemia (AML). In the past 15 years, diagnostic evaluations, prognostication, and treatment of MDS have improved substantially. However, with the discovery of molecular markers and advent of novel targeted therapies, new challenges have emerged in the complex field of MDS. For example, MDS-related molecular lesions may be detectable in healthy individuals and increase in prevalence with age. Other patients exhibit persistent cytopenia of unknown etiology without dysplasia. Although these conditions are potential pre-phases of MDS they may also transform into other bone marrow neoplasms. Recently identified molecular, cytogenetic, and flow-based parameters may add in the delineation and prognostication of these conditions. However, no generally accepted integrated classification and no related criteria are as yet available. In an attempt to address this challenge, an international consensus group discussed these issues in a working conference in July 2016. The outcomes of this conference are summarized in the present article which includes criteria and a proposal for the classification of pre-MDS conditions as well as updated minimal diagnostic criteria of MDS. Moreover, we propose diagnostic standards to delineate between 'normal', pre-MDS, and MDS. These standards and criteria should facilitate diagnostic and prognostic evaluations in clinical studies as well as in clinical practice.",
keywords = "Diagnostic criteria, Myelodysplasia, pre-MDS conditions, Standardization",
author = "Peter Valent and Attilio Orazi and Steensma, {David P.} and Ebert, {Benjamin L.} and Detlef Haase and Luca Malcovati and {van de Loosdrecht}, {Arjan A.} and Torsten Haferlach and Westers, {Theresia M.} and Wells, {Denise A.} and Aristoteles Giagounidis and Michael Loken and Alberto Orfao and Michael L{\"u}bbert and Arnold Ganser and Hofmann, {Wolf Karsten} and Kiyoyuki Ogata and Julie Schanz and B{\'e}n{\'e}, {Marie C.} and Gregor Hoermann and Sperr, {Wolfgang R.} and Karl Sotlar and Peter Bettelheim and Reinhard Stauder and Michael Pfeilst{\"o}cker and Horny, {Hans Peter} and Ulrich Germing and Peter Greenberg and Bennett, {John M.}",
year = "2017",
doi = "10.18632/oncotarget.19008",
language = "English",
volume = "8",
pages = "73483--73500",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "43",

}

Valent, P, Orazi, A, Steensma, DP, Ebert, BL, Haase, D, Malcovati, L, van de Loosdrecht, AA, Haferlach, T, Westers, TM, Wells, DA, Giagounidis, A, Loken, M, Orfao, A, Lübbert, M, Ganser, A, Hofmann, WK, Ogata, K, Schanz, J, Béné, MC, Hoermann, G, Sperr, WR, Sotlar, K, Bettelheim, P, Stauder, R, Pfeilstöcker, M, Horny, HP, Germing, U, Greenberg, P & Bennett, JM 2017, 'Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions' Oncotarget, vol. 8, no. 43, pp. 73483-73500. https://doi.org/10.18632/oncotarget.19008

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. / Valent, Peter; Orazi, Attilio; Steensma, David P.; Ebert, Benjamin L.; Haase, Detlef; Malcovati, Luca; van de Loosdrecht, Arjan A.; Haferlach, Torsten; Westers, Theresia M.; Wells, Denise A.; Giagounidis, Aristoteles; Loken, Michael; Orfao, Alberto; Lübbert, Michael; Ganser, Arnold; Hofmann, Wolf Karsten; Ogata, Kiyoyuki; Schanz, Julie; Béné, Marie C.; Hoermann, Gregor; Sperr, Wolfgang R.; Sotlar, Karl; Bettelheim, Peter; Stauder, Reinhard; Pfeilstöcker, Michael; Horny, Hans Peter; Germing, Ulrich; Greenberg, Peter; Bennett, John M.

In: Oncotarget, Vol. 8, No. 43, 2017, p. 73483-73500.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

AU - Valent, Peter

AU - Orazi, Attilio

AU - Steensma, David P.

AU - Ebert, Benjamin L.

AU - Haase, Detlef

AU - Malcovati, Luca

AU - van de Loosdrecht, Arjan A.

AU - Haferlach, Torsten

AU - Westers, Theresia M.

AU - Wells, Denise A.

AU - Giagounidis, Aristoteles

AU - Loken, Michael

AU - Orfao, Alberto

AU - Lübbert, Michael

AU - Ganser, Arnold

AU - Hofmann, Wolf Karsten

AU - Ogata, Kiyoyuki

AU - Schanz, Julie

AU - Béné, Marie C.

AU - Hoermann, Gregor

AU - Sperr, Wolfgang R.

AU - Sotlar, Karl

AU - Bettelheim, Peter

AU - Stauder, Reinhard

AU - Pfeilstöcker, Michael

AU - Horny, Hans Peter

AU - Germing, Ulrich

AU - Greenberg, Peter

AU - Bennett, John M.

PY - 2017

Y1 - 2017

N2 - Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid neoplasms characterized by peripheral cytopenia, dysplasia, and a variable clinical course with about 30% risk to transform to secondary acute myeloid leukemia (AML). In the past 15 years, diagnostic evaluations, prognostication, and treatment of MDS have improved substantially. However, with the discovery of molecular markers and advent of novel targeted therapies, new challenges have emerged in the complex field of MDS. For example, MDS-related molecular lesions may be detectable in healthy individuals and increase in prevalence with age. Other patients exhibit persistent cytopenia of unknown etiology without dysplasia. Although these conditions are potential pre-phases of MDS they may also transform into other bone marrow neoplasms. Recently identified molecular, cytogenetic, and flow-based parameters may add in the delineation and prognostication of these conditions. However, no generally accepted integrated classification and no related criteria are as yet available. In an attempt to address this challenge, an international consensus group discussed these issues in a working conference in July 2016. The outcomes of this conference are summarized in the present article which includes criteria and a proposal for the classification of pre-MDS conditions as well as updated minimal diagnostic criteria of MDS. Moreover, we propose diagnostic standards to delineate between 'normal', pre-MDS, and MDS. These standards and criteria should facilitate diagnostic and prognostic evaluations in clinical studies as well as in clinical practice.

AB - Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid neoplasms characterized by peripheral cytopenia, dysplasia, and a variable clinical course with about 30% risk to transform to secondary acute myeloid leukemia (AML). In the past 15 years, diagnostic evaluations, prognostication, and treatment of MDS have improved substantially. However, with the discovery of molecular markers and advent of novel targeted therapies, new challenges have emerged in the complex field of MDS. For example, MDS-related molecular lesions may be detectable in healthy individuals and increase in prevalence with age. Other patients exhibit persistent cytopenia of unknown etiology without dysplasia. Although these conditions are potential pre-phases of MDS they may also transform into other bone marrow neoplasms. Recently identified molecular, cytogenetic, and flow-based parameters may add in the delineation and prognostication of these conditions. However, no generally accepted integrated classification and no related criteria are as yet available. In an attempt to address this challenge, an international consensus group discussed these issues in a working conference in July 2016. The outcomes of this conference are summarized in the present article which includes criteria and a proposal for the classification of pre-MDS conditions as well as updated minimal diagnostic criteria of MDS. Moreover, we propose diagnostic standards to delineate between 'normal', pre-MDS, and MDS. These standards and criteria should facilitate diagnostic and prognostic evaluations in clinical studies as well as in clinical practice.

KW - Diagnostic criteria

KW - Myelodysplasia

KW - pre-MDS conditions

KW - Standardization

UR - http://www.scopus.com/inward/record.url?scp=85030105932&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19008

DO - 10.18632/oncotarget.19008

M3 - Review article

VL - 8

SP - 73483

EP - 73500

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 43

ER -